Cittadine Andrew, the Chief Operating Officer of Monopar Therapeutics, has made notable stock transactions as disclosed in a recent SEC filing. This activity, reported on October 2, 2026, is significant as it reflects Andrew's ongoing commitment to the company and its strategic direction.
Monopar Therapeutics, which operates under the SIC code for pharmaceutical preparations, focuses on developing innovative therapies for patients with cancer. The company is based in Wilmette, Illinois, and trades under the ticker symbol MNPR.
The filing reveals that Andrew acquired a total of 4,384 shares of common stock on September 30, 2026. Additionally, Andrew disposed of 1,944 shares, which were withheld to cover tax obligations related to the vesting of restricted stock units. Following these transactions, Andrew retains ownership of 59,998 shares of Monopar's common stock.
These transactions may affect investor sentiment regarding Monopar Therapeutics, particularly in light of Andrew's role as COO. Executive stock transactions are often closely monitored by investors, as they can signal confidence in the company's prospects.
The filing does not specify what actions will follow these transactions, leaving future developments uncertain.
Details of Stock Transactions
In the recent SEC filing, Andrew's acquisition of 4,384 shares on September 30, 2026, was part of the vesting and settlement of restricted stock units. This indicates a significant moment in his compensation structure, as these shares were granted previously and are now being realized as common stock.
Furthermore, the filing specifies that the 1,944 shares disposed of were withheld to cover tax obligations incurred from the vesting of these restricted stock units. The price per share for the disposed shares was reported at $79.67, highlighting the financial implications of tax liabilities in executive compensation.
Following these transactions, Andrew's total ownership of Monopar's common stock stands at 59,998 shares. This includes the shares acquired through the vesting of restricted stock units, which reflects a direct ownership stake in the company.
Additional Context on Restricted Stock Units
The filing also provides insight into the restricted stock units granted to Andrew. He received a total of 15,647 restricted stock units on February 1, 2023, which are set to vest over a period extending until December 31, 2026. This structured vesting schedule is designed to align Andrew's interests with the long-term performance of Monopar Therapeutics.
Moreover, Andrew was granted additional restricted stock units on March 4, 2025, and December 2, 2025, which will vest in a similar phased manner, ensuring that he continues to have a vested interest in the company's future success.
"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer," the filing notes, emphasizing the potential for future ownership increases as these units vest.
Overall, the filing illustrates Andrew's ongoing financial commitment to Monopar Therapeutics, as well as the structured nature of his compensation through equity, which may further influence investor perception.